These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34958982)

  • 21. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to compare the efficacy of biologic agents in asthma.
    Viswanathan RK; Busse WW
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):137-149. PubMed ID: 32387169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological treatments for severe asthma: where do we stand?
    Busse WW
    Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):509-518. PubMed ID: 30299397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management.
    Arnold RJ; Massanari M; Lee TA; Brooks E
    Manag Care; 2018 Jul; 27(7):34-41. PubMed ID: 29989900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment for Severe Asthma in Children: What About Biologics?
    Pansare M; Seth D; Kamat D; Poowuttikul P
    Pediatr Ann; 2021 May; 50(5):e206-e213. PubMed ID: 34044704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
    Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID;
    Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and application of induced sputum analysis in childhood asthma.
    Covar RA; Spahn JD; Martin RJ; Silkoff PE; Sundstrom DA; Murphy J; Szefler SJ
    J Allergy Clin Immunol; 2004 Sep; 114(3):575-82. PubMed ID: 15356559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type-2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide.
    Southworth T; Van Geest M; Singh D
    Clin Transl Sci; 2021 Jul; 14(4):1259-1264. PubMed ID: 34106513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Workup of Severe Asthma.
    Couillard S; Jackson DJ; Wechsler ME; Pavord ID
    Chest; 2021 Dec; 160(6):2019-2029. PubMed ID: 34265308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.
    Rogers L; Jesenak M; Bjermer L; Hanania NA; Seys SF; Diamant Z
    Respir Med; 2023 Nov; 218():107414. PubMed ID: 37776915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels.
    Haughney J; Morice A; Blyth KG; Lee AJ; Coutts A; McKnight E; Pavord I
    Respir Med; 2018 Jan; 134():117-123. PubMed ID: 29413497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asthma biologics: Comparing trial designs, patient cohorts and study results.
    Doroudchi A; Pathria M; Modena BD
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):44-56. PubMed ID: 31655122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
    Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
    Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
    Petsky HL; Li A; Chang AB
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD005603. PubMed ID: 28837221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach.
    Bossley CJ; Fleming L; Ullmann N; Gupta A; Adams A; Nagakumar P; Bush A; Saglani S
    J Allergy Clin Immunol; 2016 Aug; 138(2):413-420.e6. PubMed ID: 27061250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologics for severe asthma-Which, when and why?
    Shah PA; Brightling C
    Respirology; 2023 Aug; 28(8):709-721. PubMed ID: 37222237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.
    Porsbjerg CM; Sverrild A; Lloyd CM; Menzies-Gow AN; Bel EH
    Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32586879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?
    Koenderman L; Hassani M; Mukherjee M; Nair P
    Allergy; 2021 Apr; 76(4):1294-1297. PubMed ID: 33301608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.